Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilars

Pfizer’s Biosimilar of Roche’s Rituxan Succeeds in Study

Reuters Staff  |  

(Reuters)—Pfizer Inc said on Wednesday its biosimilar of Roche’s Rituxan was as effective as the original drug in treating patients with a type of follicular lymphoma, meeting the main goal of a study. The success of Pfizer’s biosimilar comes as Rituxan’s U.S. patent is set to expire later this year. The drug had raked in…

Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

  |  

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Rheumatologists from Minnesota Team with Dakotas’ Colleagues to Form State Society

  |  

Generating articles of incorporation, convening boards of directors, establishing nonprofit status: It’s no small feat to form a state rheumatology society, but with the right expertise, the results can be successful, according to the president of the Rheumatology Association of Minnesota and the Dakotas, Jody Hargrove, MD, who is in private practice with Arthritis &…

ACR Advocacy: Past Wins, Future Outlook

Angus Worthing, MD, FACP, FACR  |  

Greetings, advocates! Your government is back to work after ending a brief government shutdown by passing a short-term continuing resolution (CR), which will keep the government running at current funding levels into February. At some point, it would be great for Congress to pass a budget (instead of a CR) and to enact bipartisan plans…

The ACR’s 2018 Legislative & Regulatory Priorities

  |  

A recent Politico article outlined the looming agenda facing Congress as 2018 begins: Fund the government, raise the debt ceiling, modify spending caps, address healthcare subsidies, allocate additional funds for disaster relief, and address the status of millions of undocumented young immigrants.1 Amid all that activity, the ACR, through its Government Affairs Committee (GAC) and…

Meet Chris Adams, MD, the New Chair of the ACR’s Affiliate Society Council

  |  

What initially strikes people about Christopher Adams, MD, FACP, FACR, is his passion for fairness. In 2015, he told readers of The Rheumatologist, “Patients often feel powerless to fight the system and advocate for themselves, and many of my patients felt they lacked a mechanism for addressing their concerns. That’s where we come in.” Dr….

Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval

Tamara Mathias  |  

(Reuters)—The U.S. Food and Drug Administration approved Pfizer Inc’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer’s Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn’s disease and skin disorder plaque psoriasis, the drugmaker said. Biosimilars are medicines deemed…

Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More

Angus Worthing, MD, FACP, FACR   |  

Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….

Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

Deena Beasley  |  

(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…